Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP972164priorityCriticalpatent/ECSP972164A/en
Publication of ECSP972164ApublicationCriticalpatent/ECSP972164A/en
La vacuna viva recombinante aviaria comprende, como vector, un virus ILTV que comprende y expresa al menos una secuencia nucleotídica heteróloga, estando insertada esta secuencia nucleotídica en el sitio de la inserción definido entre los nucleotídicos 1624 y 3606 en SEQ ID No. 5.La vacuna puede comprender en particular una secuencia codificante para un antígeno de un agente patógeno aviario elegido del grupo que comprende el virus de la enfermedad de Gumbore (IBDV), el virus de la enfermedad de Marek (MDV), el virus de la bronquitis infecciosa (IBV), el virus de la anemiadel pollo (CAV), el virus de la neumovirosis del pollo, preferiblemente bajo el control de un promotor eucariótico fuerte. Fórmula de vacuna multivalente.The live recombinant avian vaccine comprises, as a vector, an ILTV virus that comprises and expresses at least one heterologous nucleotide sequence, this nucleotide sequence being inserted at the insertion site defined between nucleotides 1624 and 3606 in SEQ ID No. 5. Vaccine may in particular comprise a coding sequence for an antigen of an avian pathogen chosen from the group comprising Gumbore disease virus (IBDV), Marek's disease virus (MDV), infectious bronchitis virus ( IBV), chicken anemia virus (CAV), chicken pneumovirus virus, preferably under the control of a strong eukaryotic promoter. Multivalent vaccine formula.
ECSP9721641997-06-251997-06-25
VACCINES FOR AVIARY USE BASED ON INFECTIOUS LARYNG TRACHEITIS VIRUSES
ECSP972164A
(en)
PARAMYXOVIRUS AVIAR cDNA (PARTICULARLY VIRUS OF NEWCASTLE DISEASE), RNA, METHOD TO GENERATE COPIES OF INFECTIOUS VIRUS VIRUSES, COPY OF INFECTIVE VIRUSES, VACCINE THAT INCLUDES SUCH VIRUS VIRUSED VACCINES, VACCINE VACCINES Y
ADJUSED DNA VACCINE AND USE OF AN ELECTED COMPOUND BETWEEN ACRYLIC OR METACRYLIC ACID POLYMERS AND MALEIC ANHYDRIDE AND ALQUENILE DERIVATIVE COPOLYMERS TO ADJUDE SUCH DNA VACCINE
Use of an infectious bronchitis virus and Escherichia coli model infection to assess the ability to vaccinate successfully against infectious bronchitis in the presence of maternally‐derived immunity
classical infectious bursal disease virus mutant, vaccine for use in the protection of poultry, and methods for the preparation of a classical infectious bursal disease virus mutant and for the preparation of a vaccine